UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ | --- | --- | |-------------------------------------------------------------------------------------------------|-------------------------------| | Comm ...

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. About CytomX Therapeutics A live webcast of the presentation will be available on the Event ...

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. About CytomX Therapeutics A live webcast of the presentation will be available on the Event ...

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. "It is a privilege to work with the incredibly talented team at CytomX, and I am thrilled to assume the CFO role and to continue to help lead the company through this next chapter, as we pursue our vision to transform lives with safer, more e ...

"Chris has made broad contributions as a member of the CytomX executive team and is a proven crossfunctional leader within the organization," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "We are excited to announce this promotion, which is a reflection of Chris' financial acumen, strategic leadership and deep commitment to CytomX's mission." About CytomX Therapeutics This press release includes forward-looking statements. Such forward-looking statements involve known and unkn ...

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience. This doesn't mean you must choose from well-known tickers. Even if a penny stock comes from a publicly traded company with genuine potential, everything from macroeconomic trends to legal actions can bring down the company. It's important to remember that every com ...

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. The stock options were granted pursuant to the Company's 2019 Employment ...

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. The stock options were granted pursuant to the Company's 2019 Employment ...

CytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company.CytomX Therapeutics’ latest clinical trial update covers its Phase 1a study of CX-904, a cancer treatment in development. The company notes that the current results show a favorable safety profile and anti-cancer activity.However, diving into the data better explains why investors aren’t happy. Of the six pancreatic cancer patients able to be evaluated ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Results Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Wayne Chu - Chief Medical Officer Conference Call Participants Peter Lawson - Barclays Roger Song - Jefferies Joe Catanzaro - Piper Sandler Etzer Darout - BMO Capital Markets Anupam Rama - JPMorgan Mitchell Kapoor - H. C. Wainwright Operator Good day, and thank you for standing by. ...